Navigation Links
A Breakthrough in the Study of Hepatitis C

Researchers have devised a novel viral culture system, which makes way for a better study of Hepatitis C virus. This system enables the replication of virus// (isolated from patient) in non-transformed hepatocytes. Systems in vogue involve culture of permissive viral strains in transformed cell lines.

The study report by Lázaro et al, ‘Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes,’ appears in the February issue of The American Journal of Pathology.

Hepatitis C virus (HCV) infection affects approximately 170,000,000 people worldwide. HCV liver disease, which may induce liver inflammation, cirrhosis, and/or hepatocellular carcinoma, represents the foremost reason for liver transplantation in much of the U.S.

Study of HCV replication within liver cells, or hepatocytes, has been hampered by a lack of adequate virus culture systems. Some systems allow the virus to infect cells but do not permit prolonged replication and production of virus, while other systems rely on derivatives of permissive virus isolates for efficient replication in transformed (mutated) cell lines. Still lacking has been a system to sustain replication of novel virus isolates from patients using nontransformed hepatocytes.

Nelson Fausto of the University of Washington School of Medicine has crossed this hurdle using a human fetal hepatocyte culture system that was previously developed in his lab. Using this system, his group has demonstrated sustained replication and production of virus particles for at least 2 months, with these virus particles able to infect new cells.

In their first experiments, Fausto and colleagues transfected hepatocyte cultures with HCV genomic RNA and found replication of HCV RNA genomes and production of core protein (for virus particle formation). Release of infectious virus particles was confirmed, as media from these cells were able to infect naive hepatocytes. Finally, virus particles were examined by electron microscopy and shown to possess the expected size and shape of HCV virus particles.

Once the system was established, the group examined whether sera from patients carrying HCV could infect the human fetal hepatocytes. When sera from patients infected with different HCV strains were added to the hepatocyte culture system, viral replication occurred and new virus particles were produced.

In both transfection and infection models, virus particles were released in a cyclical manner, with bursts of virus produced every 10-14 days. This is similar to what has been reported during clinical HCV infection, possibly due to the host's natural defenses. Interestingly, cultured hepatocytes responded to viral replication by displaying signs of distress and cell death and by expressing interferon-beta, a cellular antiviral, in an effort to control the infection.

This culture system provides a breakthrough in studying HCV replication in nontransformed hepatocytes, the natural target of the virus. By allowing infection by patient serum containing a wide array of virus strains, this system may allow better understanding of the differences between different strains, further improving treatment strategies.

Source-Eurekalert
RI
'"/>




Related medicine news :

1. Sperm washing helps couples – Breakthrough in focu
2. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
3. Breakthrough in eye treatment
4. Genetic Breakthrough in Common Eye Problem
5. Breakthrough in cancer therapy
6. Breakthrough in Type II Diabetes
7. Breakthrough In Stem Cell Work
8. A Likely Breakthrough For Prostate Cancer Patients
9. New DNA Breakthrough Can Change Future Of Medicine
10. Breakthrough In New Vaccine For Malaria
11. Medical Breakthrough - Kidney Transplant Recipient Survives Without Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... ... the launch of Care Management Alerts and Dashboards, an innovative new service enabling ... Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data about ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, ... proposed healthcare bill to repeal and replace the Affordable Care Act (ACA). Like ... make significant cuts to Medicaid, a public health insurance program for low-income children, ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today ... is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). ... Restaurant Group who owns three other locations in the Topeka and Bonner Springs, Kan. ...
(Date:6/23/2017)... ... 23, 2017 , ... Georgia State University will host the ... The two-day conference is focused on advancing scientific knowledge about the aggressive triple ... eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” , ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
Breaking Medicine Technology: